Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
19 August 2025 | Story Martinette Brits
Dr Tlou Raphela-Masuku
Dr Tlou Raphela-Masuku, Senior Lecturer in the UFS Disaster Management Training and Education Centre for Africa (DiMTEC), was selected as one of 15 early-career researchers from Southern and Eastern Africa to join the British Academy-funded International Writing Workshop on Climate Change Adaptation.

Dr Tlou Raphela-Masuku, Senior Lecturer in the University of the Free State (UFS) Disaster Management Training and Education Centre for Africa (DiMTEC), has been selected as one of only 15 early-career researchers from Southern and Eastern Africa to participate in the prestigious British Academy-funded International Writing Workshop on Climate Change Adaptation.

Her selection follows a highly competitive process involving applicants from across the region, underscoring her growing influence in climate research. “Being selected as one of only 15 early-career researchers from the SADC and East Africa region was truly humbling. It affirmed the value of my research and passion for climate adaptation and further motivated me to keep making a meaningful contribution in this field,” she said.

 

Strengthening research visibility and collaboration

The workshop is jointly organised by York St John University (UK), the University of the West of England (UK), the University of Nairobi (Kenya), and the University of Cape Town (South Africa). It brings together emerging scholars from a range of disciplinary backgrounds to foster interdisciplinary collaboration, strengthen academic writing and publishing skills, and develop grant proposal expertise.

For Dr Raphela-Masuku, the programme is a natural fit with her work at DiMTEC. “At DiMTEC, my work spans ecosystem-based disaster risk reduction and climate change adaptation. I am the core teacher for this module for master’s students. My recent and upcoming research, including work on flood risks and climate vulnerability among subsistence farmers, directly aligns with the themes of the workshop,” she explained.

Her focus within the programme will be on climate-induced vulnerabilities and resilience, particularly in rural and peri-urban communities, with a strong emphasis on extreme weather events and nature-based solutions. She looks forward to both the online and in-person engagements in Nairobi and Cape Town, which will run between 2025 and 2027. “These offer a fantastic opportunity for peer learning, mentorship, and deeper engagement with fellow climate researchers. Exchanging ideas face to face is always energising and often leads to lasting collaborations,” she said.

 

Advancing DiMTEC’s mission

Participation in the workshop will not only advance Dr Raphela-Masuku’s own academic profile but also strengthen DiMTEC’s regional and continental footprint. “My participation directly supports DiMTEC’s mission to build climate resilience and disaster preparedness across Africa. It strengthens our footprint in the region and facilitates collaboration with other institutions working on similar challenges, especially in rural vulnerability and adaptation,” she noted.

She sees the experience as a vital platform to amplify her work on flood resilience and the health impacts of climate change to audiences that include academics, policymakers, and practitioners. “The workshop will enhance the visibility of my work and provide the tools and strategies to navigate high-impact publishing, which is crucial for emerging African scholars,” she added.

Reflecting on her journey, Dr Raphela-Masuku said it has been “rooted in both academic enquiry and real-world impact”, driven by the urgent need to support vulnerable communities. Her advice to aspiring researchers is clear: “Stay curious. Stay rooted in the needs of your communities. And don’t be afraid to ask hard questions or chase ambitious goals. Climate adaptation research is not just about publishing papers – it’s about finding real solutions for real people.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept